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Abstract 
Myohemerythrin (Mhr) is a non-heme iron O2 carrier (with two irons in the active site) that is typically found in 
the retractor muscle of marine ‘peanut’ worms. OxyMhr may either release O2, or undergo an autoxidation 
reaction in which hydrogen peroxide is released and diferric metMhr is produced. The autoxidation reaction can 
also be promoted by the addition of certain anions to Mhr solutions. This work, using recombinant Themiste 
zostericola Mhrs, contrasts the results of environmental effects on these reactions. For the O2 release reaction, 
ΔV
‡
(21.5°C)=+28±3 cm
3
 mol
-1
, ΔH
‡
(1 atm)=+22±1 kcal mol
-1
, and ΔS
‡
(1 atm)=+ 28±4 eu. The autoxidation 
reaction (pH 8.0, 21.5°C, 1 atm) displays different kinetic parameters: ΔV
‡
=-8±2 cm3 mol-1, ΔH
‡
=+24.1±0.7 
kcal mol
-1
, and ΔS
‡
=+1±1 eu. Autoxidation in the presence of sodium azide is orders of magnitude faster than 
solvolytic autoxidation. The ΔV
‡
 parameters for azide anation and azide-assisted autoxidation reaction are 
+15±2 and +59±2 cm
3
 mol
-1
, respectively, indicating that the rate-limiting steps for the Mhr autoxidation and 
anation reactions (including O2 uptake) are not associated with ligand binding to the Fe2 center. The L103V and 
L103N oxyMhr mutants autoxidize ≈10
3
–10
5
 times faster than the wild-type protein, emphasizing the 
importance of leucine-103, which may function as a protein ‘gate’ in stabilizing bound dioxygen. 
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1. Introduction 
 
Three general classes of O2 carriers [1] have been intensively studied since their discoveries in the nineteenth 
century: hemoglobins, hemocyanins, and hemerythrins. The hemoglobins, the most widespread family of 
dioxygen carriers, utilize iron porphyrin cofactors in O2 transport. Hemocyanins are binuclear copper proteins 
found in members of the mollusk and arthropod phyla. Hemerythrins contain binuclear non-heme iron active 
sites, and occur in members of four families of marine invertebrates. The coordination of molecular oxygen to 
the ferrous or cuprous deoxy centers in these proteins involves charge transfer from the metal(s), resulting in 
oxy adducts that are best described as containing either coordinated superoxide (hemoglobins) or coordinated 
peroxide (hemocyanins and hemerythrins). 
 
The hemerythrin class of O2 carriers consists of hemerythrin (Hr), an oligomer most commonly found in the 
coelomocytes of sipunculids (marine ‘peanut’ worms), and a monomeric analogue found in the retractor muscle 
of these worms, myohemerythrin (Mhr). A wealth of structural and reactivity information [2,3] makes these 
proteins, which contain an Fe–O–Fe active site per monomer, the best understood members of a growing family 
[4–10] of diiron-oxo proteins. X-ray structures [11–14] of Hrs and Mhrs indicate that the active site is 
embedded in the interior of a four-α-helix bundle, each of whose helices contributes ligands (five terminal His, 
one bridging Asp, one bridging Glu) to the diiron-oxo core. Referring to Fig. 1, Fe1 retains its six ligands in all 
forms of Mhr, while Fe2 contains a coordination site that can be occupied by a variety of mono-, di-, and linear 
triatomic ligands, including dioxygen and azide. 
 
Leucine-103 is conserved in the known amino acid sequences of Hrs and Mhrs. The side-chain methyl groups 
of this residue (see Fig. 1) are in van der Waal’s contact with bound dioxygen in the Themiste dyscrita oxyHr 
X-ray structure [11], and also with bound azide in the Themiste 
 
 
zostericola azidometMhr [12] and T. dyscrita azidometHr [13] structures. Resonance Raman studies [15,16] and 
the polarized crystal spectrum [17] of oxyHr indicate that the bound peroxide is protonated (i.e. hydroperoxide), 
and that the ligand is hydrogen-bonded to the oxo bridge, as confirmed by the oxyHr X-ray structure. Sanders-
Loehr and coworkers [15,18] have proposed that the proton involved in this hydrogen bond is derived from a 
bridging hydroxyl group in deoxyHr. 
 
The refined X-ray crystal structures (1.6–2.0 Å) of various forms [11–14] of T. dyscrita Hr and T. zostericola 
Mhr are all apparently devoid of static channels for exogenous ligands to directly access Fe2 from the solvent. 
These crystallographic data prompted us to reinvestigate the uptake and release of O2 by T. zostericola Mhr. We 
reported [19] our findings for these reactions, which do not exhibit the behavior expected for a single 
deoxyMhr+ O2 ↔ oxyMhr equilibrium step, and we further suggested that the rate-determining steps for the 
uptake and release of O2 do not coincide. As Fig. 1 indicates, oxyMhr (and oxyHr) can release O2 (Eq. (1)) or 
undergo a normally much slower autoxidation reaction (Eq. (2)) that produces the met analogue: 
 
oxyMhr[Fe(III),Fe(III)] ↔ deoxyMhr[Fe(II),Fe(II)] + O2 
2         (1)  
 
oxyMhr[Fe(III),Fe(III)] ↔ metMhr[Fe(III),Fe(III)] + H2O2  
2         (2) 
 
The met analogue of the protein is incapable of binding O2. The physiological importance of autoxidation is 
underscored by the isolation [20,21] of a cytochrome b5–cytochrome b5 reductase system in Phascolopsis 
gouldii that reduces metHr to the deoxy form. 
 
The diiron-oxo unit of Mhr has elicited a considerable amount of attention from coordination chemists. The first 
accurate structural models [22,23] for metMhr appeared in 1983. The development of oxyMhr model complexes 
[24– 27] has been more problematic, however.
3
 Understanding the relationships between O2 uptake and release 
on the one hand, and O2 release and autoxidation on the other, is an important consideration in the rational 
design of a functional Mhr model complex. 
 
In this report, we present kinetic results for reactions of the oxy and met forms of recombinant T. zostericola 
Mhrs. While release of O2 is a kinetically straightforward process involving a rate-limiting Fe–O bond cleavage, 
autoxidation is more complex, displaying kinetic parameters which suggest the rate-determining step is not 
simply associative or dissociative. The rapid autoxidation of L103V and L103N oxyMhrs suggests that the Leu-
103 side chain likely plays an important kinetic role by functioning not only as a ‘gate’ in oxygen uptake 
[19,28], but by stabilizing the oxy adduct relative to autoxidation through an important van der Waal’s contact. 
 
2. EXPERIMENTAL SECTION 
 
2.1. Myohemerythrins 
Recombinant T. zostericola wild-type metMhr was chromatographically purified [28] to homogeneity from 
Escherichia coli (BL-21 DE3) cell extracts. The L103V and L103N mutants were isolated as the apoproteins, 
stripped of adventitious metal ions, and reconstituted [28] with ferrous ammonium sulfate to produce the met 
forms. Contaminating apoproteins were removed by passage through a Whatman DE-52 ion-exchange column 
(sodium borate buffer, pH 9.0, µ =10 mM). For the wild-type and mutant proteins, purities were verified 
(>97%) by analytical isoelectric focusing, and Fe analyses (stoichiometries of 2±0.1 Fe per protein molecule 
were observed) were performed using a Perkin-Elmer 305A atomic absorption spectrometer. 
 
DeoxyMhr samples were prepared from their met analogues by degassing on a vacuum manifold, followed by 
overnight reduction under argon with an excess of buffered sodium dithionite, which was subsequently removed 
by gel filtration chromatography. Wild-type oxyMhr was prepared just prior to use by exposure of deoxyMhr to 
the laboratory atmosphere; the purity of the oxyMhr was verified spectrophotometrically. The T. zostericola 
Mhrs are insoluble at their isoelectric points (pI values —7.6), requiring all studies to be carried out above this 
pH (Attempts to reconstitute wild-type apoMhr with iron salts below the pI were unsuccessful). Mhr samples 
for kinetic experiments were prepared in 300 mM Tris-sulfate buffers (pH 8.0) (Tris-chloride buffer interferes 
with kinetic measurements, particularly autoxidation reactions). The ionization constants of Tris exhibit 
negligible dependencies on pressure [29], and their known temperature dependencies [30] were taken into 
account in preparing buffers for the kinetic runs. 
 
2.2. Kinetic measurements 
The pH and temperature dependencies of the autoxidation kinetics of wild-type Mhr (samples were -70 µM) 
were obtained at atmospheric pressure using a Hewlett-Packard Model 8452A diode array spectrophotometer. 
The reaction was followed by monitoring the loss of the hydroperoxo→Fe
III
 ligand-to-metal charge-transfer 
transition, centered at 500 nm. The pressure dependence of the autoxidation kinetics was obtained using a 
quartz ‘pill box’ optical cell [31] (≈15 mm path length) contained within a pressurizable shroud [32], 
constructed of stainless steel and containing three sapphire windows. The shroud was seated into a Cary 2215 
spectrophotometer that was equipped with an external thermostatting coil (±0.1°C) and was pressurized with 
liquid n-heptane between 1 and 1000 bar. No indications of pressure-induced protein denaturation or active site 
perturbations were observed in the optical spectra of the samples in this pressure range [19] (or even when 
pressurized to 2000 bar). Autoxidation data for wild-type oxyMhr were acquired for only two half-lives (t1/2~19 
h at 21.5°C) due to the slowness of these reactions. The autoxidations of the L103V and L103N oxyMhr 
mutants were followed (12°C, 1 bar, pH 8.0), owing to their rapidity, by reacting the deoxy proteins (0.2 mM) 
with O2 (>0.4 mM) using the stopped-flow spectrophotometer described below, and observing the decays of the 
oxy intermediates to their respective met forms at 500 nm. 
 
                                               
3 A stable hydroperoxide adduct of a dinuclear Fe(III) complex at —78°C has been recently reported [27]. 
O2 release reactions of wild-type oxyMhr, resulting in deoxyMhr formation, were studied (4–5 half-lives) using 
a custom-built stopped-flow spectrophotometer [19,33] that has a 10-ms dead time, and incorporates a syringe 
drive assembly and observation cell (500 nm monitoring wavelength) within a high-pressure vessel. The vessel 
was also fitted with an external thermostatting coil (±0.1°C) and pressurized with liquid n-heptane between 1 
and 1000 bar. Sodium dithionite (25 mM; syringe 1) was used to scavenge O2 from Mhr solutions (150 µM 
protein; 0.1 mM O2; syringe 2), initiating O2 release. Solutions in the syringes were allowed to equilibrate for at 
least 20 min after each pressure change. The temperature dependence of the O2 release reaction (at 1 bar) was 
obtained using a Durrum stopped-flow spectrophotometer in which the reactant solutions were allowed to 
equilibrate for 1 h after each temperature change. The results of at least five reactions were averaged per data 
point reported herein. 
 
Azidomet formation (wild-type Mhr) was followed (21.5°C, 1 bar, pH 8.0) using a Cary 2215 
spectrophotometer (500 nm), for at least four half-lives, with azide in sufficient excess (>20 mM) over metMhr 
(30 µM) to ensure pseudo-first-order kinetics. The high pressure stopped-flow system, described above, was 
used to determine kinetic activation parameters for the azide anation and azide-assisted autoxidation reactions. 
In the latter case, azidometMhr formation was also monitored at 500 nm. (AzidometMhr has a strong 
azide→Fe
III
 ligand-to-metal charge-transfer transition band; the difference in the e500 for oxyMhr and 
azidometMhr is well characterized) [28]. Varying concentrations of azide were reacted with 90 µM protein (60 
µM oxyMhr +30 µM metMhr) to produce the azidometMhr product.
4
 
 
All kinetic data reported in this work were analyzed with KINFIT 3.0 software obtained from On-Line 
Instruments (Bogart, GA). Experimental uncertainties (estimated as ±one standard deviation from the mean) 
associated with individual points in Figs. 2–6 that do not contain error bars are contained within those points. 
 
3. RESULTS 
 
The reactions (pH 8.0, 12.0°C, 1 atm) of the deoxy L103V and L103N Mhrs with O2 were both found to be 
biphasic. Stopped-flow traces (500 nm) of these reactions all display a rapid absorbance increase, due to 
formation of the respective oxyMhr intermediate, followed by a slower phase (attributed to autoxidation) that 
ultimately leads to a buildup of the met protein. More importantly, the decrease in OD500, due to formation of 
the L103V metMhr form, occurs with an observed rate constant of 0.22±0.04 s
-1
, more than five orders of 
magnitude faster than that observed for autoxidation of the wild-type protein. The decomposition of the 
oxyL103NMhr is also faster, occurring with an observed rate constant of (2.4±0.1)X10
-3
 s
-1
. Fig. 2 displays 
absorbance vs. log time plots for the second kinetic phases. We did not observe any UV–Vis spectral evidence 
for additional Mhr species (i.e. other than deoxy, oxy, or met forms), possibly indicative of oxidase activity for 
the L103V or L103N mutants. The met forms of the mutants do not react with hydrogen peroxide. 
 
DeoxyMhr formation was studied [19] by dithionite scavenging of dissolved O2 from solutions containing 
oxyMhr, O2 (0.4–1.5 mM), and Na2S2O4 (50–300 mM). The primary reductant in these reactions is the SO2 
radical, which rapidly equilibrates with S2O4 in aqueous 
                                               
4 The [N3] dependence of the rates of azide assisted autoxidation of oxyMhr and azide anation of metMhr reactions were measured 
simultaneously by mixing various concentrations of azide with a mixture of oxyMhr and metMhr. The observed rates of these 
reactions differ by more than two orders of magnitude at the lowest concentration of azide used and the kinetic steps can be easily 
resolved. 
 
 
solutions [34] (H2O2 is also scavenged). Sulfite, generated from the oxidation of dithionite, does not bind to the 
active site of Mhr; other products of the O2 and S2O4
2
 reaction do not interfere with the deoxygenation kinetics 
[35,36].
5
 Temperature-dependent data (pH 8.0, 1 bar) are plotted in Fig. 3 for solvolytic autoxidation. The onset 
of thermal denaturation [37] occurs at —29°C, setting an upper limit to the temperature range employed in this 
study. Table 1 summarizes rate data
6
, including volumes of activation, for these reactions. 
 
Azide accelerates [38,39] the autoxidation process, as do other small anions (e.g. Cl-, F-, and CNO ). The 
product of the azide-assisted autoxidation of oxyMhr is azidometMhr. This orange-colored adduct can also be 
produced by the direct anation of metMhr. In both cases, the observed rate exhibits a hyperbolic
7
; rather than a 
linear, dependence on [N3] (see Table 2). Both anation and azide-assisted autoxidation rate constants (kcaj were 
determined by fitting kobs to an expression of the form kcalc[N3]/{Kd+[N3]j. Fig. 4 displays the observed rates 
(21.5°C, 1 bar, pH 8.0) of azide anation and assisted autoxidation as a function of [N3]. The temperature 
dependencies (1 bar, pH 8.0, 300 mM NaN3) of kobs for azide-assisted autoxidation and kcalc for azide anation 
are shown in Fig. 5. The pressure dependencies (21.5°C, pH 8.0) of solvolytic autoxidation, azide-assisted 
autoxidation, and azide anation are displayed in Fig. 6. Table 2 summarizes the results of the azide experiments. 
 
 
 
 
                                               
5 O2 trapping, not reductive decay of the µ-1,2-peroxodiiron(III) active site, is shown to occur as the colorless deoxyMhr (diferrous µ-
oxy) product is obtained (not the diferric metMhr). 
6 The relative rates for L1 03V and L1 03N autoxidation were inadvertently juxtaposed in Ref. [28]. 
7 Azide anation of metMhr data have been reported before [28]; saturation kinetics for this reaction is only observed at relatively high 
azide concentrations. 
4. DISCUSSION 
 
The importance of protein conformational fluctuations has been noted describing the kinetic steps involved in 
the O2 uptake and release reactions of Mhr and Hr [19,40]. That such fluctuations are of major importance in 
ligand binding and release is evident from an inspection of X-ray crystal structures [11–14] of various forms of 
these proteins: the absence of a static channel linking the protein active site with the solvent indicates that 
ligand substitutions must be multistep processes. 
 
In the case of T. zostericola Mhr, the onset of thermal denaturation occurs at —29°C, setting the upper limit to  
the accessible temperature range for kinetic studies. This lowers somewhat the reliability of ΔS
‡
 as a 
mechanistic indicator. More importantly, our results for Mhr (Tables 1 and 2, Ref. [19]) demonstrate that the 
sign of ΔS
‡
 cannot be used to assert whether an observed rate represents ligand binding to Fe2 in the active site 
or elsewhere in the protein. For example, the step limiting the O2 uptake rate likely involves [19] a protein 
fluctuation, rather than Fe–O bond formation. Additionally, measurements of metalloprotein activation volumes 
[41] can be done with more accuracy and also provide more useful probes of dynamics. 
 
The activation parameters [19] for the release of O2 by oxyMhr (Table 1) all reflect a rate-limiting step that 
involves a simple Fe–O bond dissociation. In particular, we note that ΔV
‡
 = +28±3 cm
3
 mol
-1
, which exactly 
corresponds to the value for the partial molar volume of O2. Projahn et al. [42] also reported a positive ΔV
‡
 for 
O2 release by T. zostericola Hr, which they attributed to Fe2–O2 bond breakage and/or reduction of Fe(III) to 
Fe(II). 
 
The autoxidation of oxyMhr results in the formation of metMhr, and is believed to be accompanied by the 
release of hydrogen peroxide [1]. This process would be of little consequence in the case of wild-type oxyMhr, 
except for the fact that it is likely irreversible in vivo in the absence of reductase proteins. The contrasting signs 
of the activation volumes for O2 release and autoxidation (pH 8.0) indicate that the rate-limiting steps of these 
reactions are markedly different — that for autoxidation is not dissociative (with respect to Fe2) in nature. The 
near-zero value for the autoxidation ΔS
‡
 is consistent with the incoming nucleophile being some form of 
protein-associated water that has low mobility
8
. Interestingly, an internal water molecule has been found, 
associated with His-25 and other residues, in the X-ray structures of metMhrs [11,14]; water molecules are also 
observed hydrogen-bonded to the protein surface. 
 
How does the protein minimize this autoxidation reaction? Refined X-ray crystal structures [11–13] of T. 
dyscrita azidomet- and oxyHrs, and T. zostericola azidometMhr place a leucine side chain in van der Waal’s 
contact with the bound ligand. This amino acid residue (10
3
 in Mhr) is conserved in all known Hr and Mhr 
sequences. O2 uptake reactions of two deoxyMhr mutants, containing either valine or asparagine at position 
103, were therefore studied by stopped-flow spectrophotometry. In both cases, the oxy adducts were found to be 
very unstable due to a surprisingly fast decay of the oxy adduct to yield met (diferric) products. In particular, 
shortening the side chain of residue 103 by one methylene linkage (L103V mutant) leads to a ≈2.3 3 10
5
 
increase in the autoxidation rate. The valine side chain cannot be in Van der Waal’s contact with bound oxygen 
as it is in the wild-type protein. The loss of steric shielding and/or greater accessibility of the solvent may be 
responsible for the increased rate.
9
 We also previously noted [28] that the rate constant for azide anation 
increases for the L103V mutant relative to the wild-type Mhr, in keeping with this view. Computer graphics 
modelling [14,37] of Mhr shows that Fe2 can be accessed from the interhelical core (and thence from the 
solvent) once the side chain of Leu-103 is rotated appropriately. Hence, we regard this residue as a protein gate, 
whose function is to shield bound O2 from nucleophilic displacement. A leucine gate has also been proposed to 
                                               
8 Solvolytic autoxidation resulting from attack on Fe2 by a water molecule from the bulk solvent would be expected to yield a DV‡ .0 
and DS‡ ,0 (reminiscent of O2 uptake) [19]. This low mobility, protein-associated water may be located in the protein matrix or 
possibly bound to its surface. 
9 The spontaneous decomposition (autoxidation) of the mutant oxyMhrs is not believed to occur by reduction of the oxygen to water 
as none of the metMhrs show any reaction with H2O2, and H2O2 does not react with any of the oxyMhrs. There is also no kinetic 
evidence for additional intermediates that might be present after mixing. 
be operative during methane monooxygenase turnover [43]. The 100-fold increase in rate constant for the 
autoxidation of the L103V Mhr mutant, relative to the rate constant for the L103N mutant, may reflect 
hydrogen bonding between bound hydroperoxide and the Asn-103 side chain (possibly involving a water 
bridge, as observed in the L103N hydroxometMhr structure) [14]. It has been suggested that the unusual 
stability of oxyMhr (and oxyHr) with respect to autoxidation is due to hydrogen bonding of the bound 
ligand with the oxo bridge [9]. Our results (Fig. 1 and Table 1) indicate this impression is incomplete, in 
agreement with recent kinetic work on model compounds [44]. Steric bulk imposed by the protein around the 
active site in oxyMhr and oxyHr (especially an aliphatic residue that is in van der Waal’s contact with bound 
hydroperoxide) appears to be a considerable factor in determining the stability of the oxy adduct with respect to 
autoxidation; this feature of Mhr will be difficult to incorporate into oxyMhr model complexes. 
 
In addition to water, small solutes can promote autoxidation of oxyMhr and oxyHr. Wilkins and coworkers 
[38,39] have noted that azide can also assist the autoxidation process, and proposed the following mechanism 
for azide-assisted autoxidation of oxyHr: 
 
Hr([Fe(III,III)]O2)8 ↔ Hr([Fe(II,II)])8 + 8O2   (3) 
 
Hr([Fe(II,II)])8 + 8HN3 ↔ Hr([Fe(II,II)]N3)8 + 8H
+
 
        (4) 
Hr([Fe(II,II)]N3
-
 )8 + 8O2 —>Hr([Fe(III,III)]N3 )8 + 8O2
2-
 
        (5) 
 
The product of the last step (Eq. (5)), azidometHr, can also be produced by direct anation of metHr. The azide-
assisted autoxidation and anation [28] reactions are also observed with Mhr. Azide-assisted autoxidation of 
oxyMhr and oxyHr is accelerated by acid (results not shown and Ref. [45]), indicating that the species entering 
the protein matrix is likely HN3. Since the first two steps are fast (see the Results section and Ref. [46]), this 
mechanism requires that the last step be rate determining. The initial step (Eq. (3)) of the Wilkins azide-assisted 
autoxidation mechanism was proposed [38] partly to explain a rapid bleaching of the hydroperoxo—>Fe
III
 
charge-transfer transition that is responsible for the purple color of oxyMhr and oxyHr. This step cannot be 
operative unless O2 is present in low concentration.
10
 10 More importantly, two-electron outer-sphere oxidation 
of azidodeoxyMhr by O2 (Eq. (5)) is very unlikely to be concerted, as the Fe1 and Fe2 centers are 
nonequivalent. Two single-electron oxidation steps are also implausible, since the second would be 
thermodynamically unfavorable [47,48]. 
 
As Fig. 5 illustrates, saturation kinetics are observed for both azide anation of metMhr and azide-assisted 
catalysis of oxyMhr autoxidation. This suggests that azide binds/ interacts with the protein matrix prior to the 
step involving ligation to Fe2.
11
 A minimal three-step mechanism is needed to discuss any ligand-binding 
reaction of a form of Mhr: 
 
 
 
                                               
10 We did not observe rapid bleaching of oxyMhr upon azide addition. The equilibrium constant for the HrO2 +N3 ↔ HrN3 +O2 
reaction at 25°C and pH 6.3 was determined to be 0.017 [38]. Low O2 and relatively high N3 concentrations would, therefore, be 
required for rapid bleaching to be observed. 
11 Although both low and high affinity anion binding sites were described for Hr in Ref. [49], the Kd for azide-anation of metMhr is so 
large that it could represent non-specific binding. The interpretation of saturation kinetics for azide anation as anion binding in a rapid 
pre-equilibrium step, prior to a protein gating step, is supported by the fact that the activation volumes for azide anation and azide-
assisted autoxidation are different from each other and from the activation volume for O2 uptake [19]. 
Here, L is a generic incoming ligand, and *Mhr denotes an alternate conformation of Mhr. Hence, Eq. (7) 
represents a protein-gating step that permits ligand entry into the ligand-binding pocket. Eq. (8) denotes the 
final step, involving a ligand substitution at Fe2. Azide entries into both metMhr and oxyMhr are characterized 
by relatively large, positive values for ΔV
‡
 (the activation volume for solvolytic autoxidation is negative). This 
indicates that the rate-limiting step of neither mechanism is associative (this would require negative activation 
volumes) with respect to ligand substitution at the Fe2 center. Since an expanded Fe2 coordination sphere is not 
indicated, these activation volumes most likely reflect protein dynamics. 
 
In oxyMhr, hydroperoxide resides in the cavity between the Fe–O–Fe core and Leu-103. The O2 binding pocket 
of oxyMhr is presumably more tightly packed than is that of metMhr, as indicated by the X-ray crystal 
structures [12,13] of analogous T. dyscrita met- and oxyHrs, accounting for the much larger activation volume 
for the azide-assisted autoxidation reaction. Our view of the solvolytic and azide-assisted autoxidations of 
oxyMhr is schematically depicted in Fig. 7. There may be more than one protein 
 
 
‘gate’ for the reactions discussed in this study, but at least one residue, leucine-103, has been shown to strongly 
influence the stability of oxyMhr in this work, as well as influence azide uptake kinetics [28]. 
 
The traditional view of metalloproteins, as ‘metal ions in disguise’, has strongly influenced mechanistic studies 
of ligand binding. However, X-ray structures of Hrs and Mhrs show that their active sites are not directly 
accessible to the solvent, indicating that protein side-chain motions play key roles in ligand binding by these 
proteins. In these situations, the mechanistic significance, with respect to the metal-ion active sites, of variations 
in temperature and incoming solute becomes blurred. For example, ΔH
‡
 for azide uptake and azide-assisted 
autoxidation are identical within experimental error (as are ΔS
‡
 values for these reactions). The activation 
volumes clearly show that the rate-limiting steps for these reactions do not involve Fe2– N3 bond formation. 
 
Similar considerations apply to other metalloproteins. In the case of myoglobin, ongoing experiments [50,51], 
using site-directed mutagenesis and photoinduced ligand (principally O2 and CO) recombination kinetics, are 
elucidating channels for ligand entry and egress. The 1.5-A X-ray crystal structure [52] of photolyzed 
carbonmonoxymyoglobin dramatically illustrates the importance of protein dynamics in determining ligand-
substitution mechanisms. Recent X-ray crystal structures of other metalloproteins, including Lumulus 
polyphemus hemocyanin [53], copper amine oxidases [54,55], cytochrome c oxidases [56–58], Klebsiella 
aerogenes urease [59], and methane monooxygenase [60], indicate that the problem of ligand access to buried 
active sites is more common than previously realized. 
 
4.1. Abbreviations 
azidodeoxyMhr  azidodeoxymyohemerythrin 
azidometHr   azidomethemerythrin  
azidometMhr   azidometmyohemerythrin 
deoxyHr   deoxyhemerythrin 
deoxyMhr   deoxymyohemerythrin 
Hr    hemerythrin 
Mhr    myohemerythrin 
oxyHr    oxyhemerythrin 
oxyMhr   oxymyohemerythrin 
T. dyscrita   Themiste dyscrita 
T. zostericola   Themiste zostericola 
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